TrialNeurology2016
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Gavin Giovannoni et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
33 papers cite it
this paperpooled ittrialcites it
TrialNeurology2016
Gavin Giovannoni et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.